Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.

OBJECTIVES The aim of this study was to determine the in vitro activity of lipiarmycin against drug-resistant strains of Mycobacterium tuberculosis (MTB) and to establish the resistance mechanism of MTB against lipiarmycin using genetic approaches. METHODS MIC values were measured against a panel of drug-resistant strains of MTB using the broth microdilution method. Spontaneous lipiarmycin-resistant mutants of MTB were tested for cross-resistance to standard anti-TB drugs, and their rpoB and rpoC genes were sequenced to identify mutations. RESULTS Lipiarmycin exhibited excellent inhibitory activity against multidrug-resistant strains of MTB with MIC values of <0.1 mg/L. Sequence analysis of the rpoB and rpoC genes from spontaneous lipiarmycin-resistant mutants of MTB revealed that missense mutations in these genes caused resistance to lipiarmycin. Although both lipiarmycin and rifampicin are known to inhibit the bacterial RNA polymerase, the sites of mutation in the rpoB gene were found to be different in MTB strains resistant to these inhibitors. Whereas all six rifampicin-resistant MTB strains tested had mutation in the 81 bp hotspot region of the rpoB gene spanning codons 507-533, 16 of 18 lipiarmycin-resistant strains exhibited mutation between codons 977 and 1150. The remaining two lipiarmycin-resistant strains had mutation in the rpoC gene. CONCLUSIONS Lipiarmycin has excellent bactericidal activity against MTB and lacks cross-resistance to standard anti-TB drugs. Furthermore, rifampicin-resistant strains remained fully susceptible to lipiarmycin, and none of the lipiarmycin-resistant MTB strains became resistant to rifampicin, highlighting the lack of cross-resistance.

[1]  A. Matteelli,et al.  Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control , 2007, Expert review of anti-infective therapy.

[2]  I. Chopra,et al.  Bacterial RNA polymerase: a promising target for the discovery of new antimicrobial agents. , 2007, Current opinion in investigational drugs.

[3]  L. Bastide,et al.  Progress in targeting bacterial transcription. , 2007, Drug discovery today.

[4]  Alan P. Johnson.  Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. , 2007, Current opinion in investigational drugs.

[5]  Mehran Hosseini,et al.  Global incidence of multidrug-resistant tuberculosis. , 2006, The Journal of infectious diseases.

[6]  L. Bastide,et al.  Mutation in the Bacillus subtilis RNA Polymerase β′ Subunit Confers Resistance to Lipiarmycin , 2006, Antimicrobial Agents and Chemotherapy.

[7]  H. Floss,et al.  Rifamycin — Mode of Action, Resistance, and Biosynthesis , 2005 .

[8]  P. Appelbaum,et al.  Activity of OPT-80, a Novel Macrocycle, Compared with Those of Eight Other Agents against Selected Anaerobic Species , 2004, Antimicrobial Agents and Chemotherapy.

[9]  F. Monti,et al.  Mode of action of the microbial metabolite GE23077, a novel potent and selective inhibitor of bacterial RNA polymerase. , 2004, European journal of biochemistry.

[10]  R. Sandaa,et al.  A multiplex polymerase chain reaction assay for genus-, group- and species-specific detection of mycobacteria. , 2004, Diagnostic microbiology and infectious disease.

[11]  D. Mitchison,et al.  The search for new sterilizing anti-tuberculosis drugs. , 2004, Frontiers in bioscience : a journal and virtual library.

[12]  D. Andersson,et al.  Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis , 2004, Antimicrobial Agents and Chemotherapy.

[13]  C. Çavuşoğlu,et al.  Characterization of rpoB Mutations in Rifampin-Resistant Clinical Isolates of Mycobacterium tuberculosis from Turkey by DNA Sequencing and Line Probe Assay , 2002, Journal of Clinical Microbiology.

[14]  E. Chan,et al.  Current medical treatment for tuberculosis , 2002, BMJ : British Medical Journal.

[15]  S. Yokoyama,et al.  Crystal structure of a bacterial RNA polymerase holoenzyme at 2.6 Å resolution , 2002, Nature.

[16]  C. Fishwick,et al.  RNA Polymerase Inhibitors with Activity against Rifampin-Resistant Mutants of Staphylococcus aureus , 2000, Antimicrobial Agents and Chemotherapy.

[17]  Strohl,et al.  The role of natural products in a modern drug discovery program. , 2000, Drug discovery today.

[18]  W. Jacobs,et al.  New use of BCG for recombinant vaccines , 1991, Nature.

[19]  J. McAlpine,et al.  Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination. , 1987, The Journal of antibiotics.

[20]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[21]  A. Sonenshein,et al.  Initiation of transcription in vitro inhibited by lipiarmycin. , 1979, Journal of molecular biology.

[22]  G. Lancini,et al.  Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization. , 1975, The Journal of antibiotics.

[23]  F. Parenti,et al.  LIPIARMYCIN, A NEW ANTIBIOTIC FROM ACTINOPLANES , 1975 .

[24]  Mark S Butler,et al.  Natural products to drugs: natural product derived compounds in clinical trials. , 2005, Natural product reports.

[25]  C. Dye,et al.  Global tuberculosis control: surveillance planning financing. WHO report 2003. , 2003 .

[26]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[27]  P. Howse,et al.  Isolation and structure determination , 1998 .